Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 424

1.

p53 predictive value for pT1-2 N0 disease at radical cystectomy.

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ.

J Urol. 2009 Sep;182(3):907-13. doi: 10.1016/j.juro.2009.05.024.

PMID:
19616250
2.

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.

Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI.

J Clin Oncol. 2005 Sep 20;23(27):6533-9.

PMID:
16116151
3.
4.

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.

Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y.

Cancer. 2008 Jan 15;112(2):315-25.

5.

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.

J Clin Oncol. 2004 Mar 15;22(6):1014-24.

PMID:
14981102
6.

Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.

Su JS, Arima K, Hasegawa M, Franco OE, Umeda Y, Yanagawa M, Sugimura Y, Kawamura J.

Int J Urol. 2004 Feb;11(2):74-82.

7.

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.

Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y.

J Urol. 2009 Jul;182(1):78-84; discussion 84. doi: 10.1016/j.juro.2009.02.125. Erratum in: J Urol. 2015 May;193(5):1730.

PMID:
19447418
8.

Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP.

J Urol. 2006 Oct;176(4 Pt 1):1354-61; discussion 1361-2.

PMID:
16952631
9.

Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.

Harada K, Sakai I, Hara I, Eto H, Miyake H.

Int J Urol. 2005 Mar;12(3):250-5.

10.

Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.

Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP.

J Urol. 2006 Jun;175(6):2048-53; discussion 2053.

PMID:
16697800
11.

Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.

Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.

J Urol. 2012 Feb;187(2):457-62. doi: 10.1016/j.juro.2011.10.031.

PMID:
22177145
12.

Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.

Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G.

J Urol. 2009 Aug;182(2):459-65; discussion 465. doi: 10.1016/j.juro.2009.04.017.

PMID:
19524971
13.
14.

Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.

Dotan ZA, Kavanagh K, Yossepowitch O, Kaag M, Olgac S, Donat M, Herr HW.

J Urol. 2007 Dec;178(6):2308-12; discussion 2313.

PMID:
17936804
15.

Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.

Boudreaux KJ Jr, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr, Chang SS.

J Urol. 2009 Feb;181(2):540-5; discussion 546. doi: 10.1016/j.juro.2008.10.038.

PMID:
19084855
16.

p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.

Rodríguez-Alonso A, Pita-Fernández S, González-Carreró J, Nogueira-March JL.

Eur Urol. 2002 Feb;41(2):182-8; discussion 188-9.

PMID:
12074407
17.

Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.

Bastian PJ, Hutterer GC, Shariat SF, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; Bladder Cancer Research Consortium..

BJU Int. 2008 Feb;101(4):450-4.

18.

The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy.

Antunes AA, Nesrallah LJ, Dall'Oglio MF, Maluf CE, Camara C, Leite KR, Srougi M.

Int Braz J Urol. 2007 May-Jun;33(3):339-45; discussion 346.

19.

Perineural invasion by transitional cell carcinoma of the bladder in patients submitted to radical cystectomy: what is the prognostic value?

Antunes AA, Nesrallah LJ, Dall'Oglio MF, Crippa A, Nesrallah AJ, Paranhos M, Leite KR, Srougi M.

Int Braz J Urol. 2007 Mar-Apr;33(2):161-6.

20.

Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.

Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT.

J Urol. 2008 Nov;180(5):1928-32; discussion 1932. doi: 10.1016/j.juro.2008.07.056.

PMID:
18801529
Items per page

Supplemental Content

Support Center